TidalHealth Richard A Henson Cancer Institute

Summary

TidalHealth Richard A Henson Cancer Institute is a medical facility located in Berlin, Maryland. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Breast cancer, Small Cell Lung Cancer and other specialties. TidalHealth Richard A Henson Cancer Institute is involved with conducting 20 clinical trials across 66 conditions. There are 4 research doctors associated with this hospital, such as John R. Mansueti, Justinian R. Ngaiza, Zeinab Abou Yehia, and Justin R. Kucinski.

Top PIs

Clinical Trials running at TidalHealth Richard A Henson Cancer Institute

Lung Cancer

Small Cell Lung Cancer

Bladder Cancer

Breast Cancer

Chronic Lymphocytic Leukemia

Lymphoma

Prostate Cancer

Colorectal Cancer

Ovarian Cancer

Esophageal cancer

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Stereotactic Radiosurgery vs Whole-Brain Radiotherapy

for Brain Metastasis from Lung Cancer

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.

Recruiting

2 awards

Phase 3

15 criteria